Skip to main content
C.Q. Pharmaceutical Holding Co., Ltd. logo

C.Q. Pharmaceutical Holding Co., Ltd. — Investor Relations & Filings

Ticker · 000950 ISIN · CNE0000010K0 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 2,883 across all filing types
Latest filing 2022-12-05 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000950

About C.Q. Pharmaceutical Holding Co., Ltd.

https://www.cqphar.com

C.Q. Pharmaceutical Holding Co., Ltd. is a comprehensive pharmaceutical enterprise specializing in the distribution, retail, and supply chain management of healthcare products. The company operates an extensive network focused on the wholesale of pharmaceuticals and medical devices, providing integrated logistics and warehousing solutions to healthcare providers and manufacturers. Its core business activities encompass the procurement and distribution of a wide range of prescription drugs, over-the-counter medications, and specialized medical equipment. Through its retail pharmacy operations and third-party logistics services, the company facilitates the efficient delivery of medical supplies. C.Q. Pharmaceutical Holding Co., Ltd. emphasizes technological integration within its supply chain to optimize inventory management and ensure the integrity of healthcare products throughout the distribution lifecycle.

Recent filings

Filing Released Lang Actions
关于参与投资设立健康产业基金的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company regarding the progress of its participation in establishing a health industry investment fund. It details amendments to the partnership agreement of the fund, including changes to the fund's duration, investment proportions, and profit distribution. The document is relatively short (1725 characters) and does not contain financial statements or detailed financial data. It is an update on a capital investment activity rather than a full financial report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-12-05 Chinese
关于控股子公司2022年度第一期资产支持票据发行结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the issuance results of asset-backed notes by a controlling subsidiary of the company. It includes details such as issuance date, total scale, types of notes, ratings, interest rates, and maturity dates. The document is relatively short (1129 characters) and focuses on the outcome of a financing activity rather than presenting comprehensive financial statements or detailed financial performance. There is no indication that this is a full financial report or an earnings release. The content aligns with updates on company fundraising and capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2022-11-30 Chinese
2022年第六次临时股东大会会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 sixth extraordinary general meeting of shareholders of the company. It includes information about the meeting date, voting methods, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, but rather the official results of shareholder votes at a general meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is under 5,000 characters and it is not merely announcing a report publication but providing full voting results and meeting details, so it is not an RPA. Therefore, the correct classification is DVA with high confidence.
2022-11-30 Chinese
北京市竞天公诚律师事务所关于重药控股股份有限公司2022年第六次临时股东大会的律师见证法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and voting results of a company's 2022 sixth extraordinary general meeting (临时股东大会). It details the legality of the meeting's call, attendance, voting procedures, and results. It does not contain financial statements or management discussion but focuses on the legal validation of the shareholder meeting and its resolutions. The document length is 3846 characters, which is relatively short and primarily serves as a legal opinion on the shareholder meeting rather than the meeting materials or voting results announcement themselves. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a legal compliance document related to the shareholder meeting, not the meeting materials (AGM-R) or voting results announcement (DVA).
2022-11-30 Chinese
关于召开2022年第六次临时股东大会的提示性公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement about the convening of the 2022 sixth extraordinary general meeting of shareholders for Chongqing Pharmaceutical Holdings Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items, registration details, and proxy authorization forms. The content focuses on notifying shareholders about the meeting logistics and agenda proposals, including the appointment of audit institutions and related party transactions. There are no financial statements, management discussion, or detailed financial results presented. The document is not a report itself but an official notice about the meeting and voting process. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than solicitation materials or proxy statements, the best fit is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 4761 characters, which is consistent with a detailed meeting notice rather than a full report. Hence, the classification is DVA with high confidence.
2022-11-25 Chinese
关于控股子公司收购重庆长圣医药有限公司股权之标的资产过渡期损益情况公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Chongqing Pharmaceutical Holdings Co., Ltd. regarding the profit and loss situation during the transition period of an asset acquisition by its controlling subsidiary. It references an audit report issued by an accounting firm on the transition period profit and loss, but the document itself is a public announcement summarizing the transaction details, audit results, and compensation arrangements. The document length is short (1217 characters), and it does not contain full financial statements or detailed financial data, but rather a summary of the audit findings and transaction terms. It is not the audit report itself but an announcement about the audit results and transaction progress. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-11-17 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.